Physician profile
Clarence E Coker
NPI 1598738593
$477.11
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $82.87 · 2021: $87.45 · 2022: $96.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $81.57 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $72.99 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $53.38 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.19 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $39.92 | 2019-2020 | |
| Pfizer INC. | $38.71 | 2019 | |
| Amgen INC. | $33.65 | 2019 | |
| Novo Nordisk INC | $29.52 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $21.83 | 2022 | |
| Hologic Sales and Service, LLC | $14.90 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.58 | 2019 | |
| Lilly USA, LLC | $12.46 | 2021 | |
| Amarin Pharma, INC. | $12.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.29 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarence Coker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.